Anticancer Drugs. 2009 Jan;20(1):81-2.

Hypertension and proteinuria: a class-effect of antiangiogenic therapies.

Source

Department of Nephrology, Pitie-Salpetriere Hospital, Paris, France. vincent.launay-vacher@psl.aphp.fr

Abstract

Antiangiogenic therapy has now become a cornerstone in the treatment of several solid tumor cancers. Those drugs present with a renal toxicity profile manifesting as proteinuria and hypertension, often reported in the literature to be linked to bevacizumab, a monoclonal antibody targeted at the circulating vascular endothelial growth factor (VEGF). However, there is evidence that those side effects are most probably related to the pharmacological action of those drugs: the inhibition of the VEGF pathway. Thus, they may occur with any antiangiogenic therapy, either those acting on circulating VEGF (bevacizumab or VEGF-trap), or those acting on VEGF receptor(s) (sunitinib, sorafenib, or axitinib). Clinicians should thus be aware of such a 'class effect' to appropriately monitor and treat their patients, regardless of which antiangiogenic drug is used.

PMID:: 19343005; [PubMed - indexed for MEDLINE]

MeSH Terms, Substances

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Supplemental Content

Related citations

Review The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. [Curr Clin Pharmacol. 2008]
Review The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.
Roodhart JM, Langenberg MH, Witteveen E, Voest EE. Curr Clin Pharmacol. 2008 May; 3(2):132-43.
Review Management of hypertension in angiogenesis inhibitor-treated patients. [Ann Oncol. 2009]
Review Management of hypertension in angiogenesis inhibitor-treated patients.
Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP. Ann Oncol. 2009 May; 20(5):807-15. Epub 2009 Jan 15.
Review VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. [Eur J Cancer. 2010]
Review VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.
Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. Eur J Cancer. 2010 Jan; 46(2):439-48. Epub 2009 Dec 16.
Review Antiangiogenic therapy in malignant glioma: promise and challenge. [Curr Pharm Des. 2007]
Review Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S, Rich JN. Curr Pharm Des. 2007; 13(35):3545-58.
Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? [J Clin Oncol. 2007]
Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
van Heeckeren WJ, Ortiz J, Cooney MM, Remick SC. J Clin Oncol. 2007 Jul 20; 25(21):2993-5.

See reviews... See all...

Cited by 3 PubMed Central articles

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. [J Natl Cancer Inst. 2011]
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS, Motzer RJ. J Natl Cancer Inst. 2011 May 4; 103(9):763-73. Epub 2011 Apr 28.
A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours. [Br J Cancer. 2010]
A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.
Boven E, Massard C, Armand JP, Tillier C, Hartog V, Brega NM, Countouriotis AM, Ruiz-Garcia A, Soria JC. Br J Cancer. 2010 Sep 28; 103(7):993-1000. Epub 2010 Aug 17.
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. [J Exp Clin Cancer Res. 2010]
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, Venzon D, Liewehr D, English BC, Baum CE, et al. J Exp Clin Cancer Res. 2010 Jul 14; 29:95. Epub 2010 Jul 14.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Anticancer Drugs. 2009 Jan ;20(1):81-2.

PubMed
Quantity and quality of sleep in the surgical intensive care unit: are our patie...
Quantity and quality of sleep in the surgical intensive care unit: are our patients sleeping?
J Trauma. 2007 Dec ;63(6):1210-4.

PubMed
Evolving clinical strategies for transplantation in the HIV-positive recipient.
Evolving clinical strategies for transplantation in the HIV-positive recipient.
Transplantation. 2007 Sep 15 ;84(5):563-71.

PubMed
DNA-dependent phosphorylation of Chk1 and Claspin in a human cell-free system.
DNA-dependent phosphorylation of Chk1 and Claspin in a human cell-free system.
Biochem J. 2005 Jun 1 ;388(Pt 2):705-12.

PubMed
Total body irradiation before an allogeneic stem cell transplantation: is there ...
Total body irradiation before an allogeneic stem cell transplantation: is there a magic dose?
Curr Opin Hematol. 2008 Nov ;15(6):555-60.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: